Literature DB >> 29384236

Incidence and risk factors associated with hepatocellular carcinoma surveillance failure.

Alejo Mancebo1, María Varela1, María Luisa González-Diéguez1, Carmen A Navascués1, Valle Cadahía1, Alicia Mesa-Álvarez2, Luis Rodrigo1, Manuel Rodríguez1.   

Abstract

BACKGROUND AND AIM: Surveillance for hepatocellular carcinoma (HCC) intends to detect tumors at an early stage to improve survival. The study aims were to assess the frequency and risk factors associated with HCC surveillance failure.
METHODS: The study analyzed data from 188 consecutive patients diagnosed with HCC within a surveillance program conducted among 1,242 cirrhotic patients and based on ultrasonography and alpha-fetoprotein (AFP) testing every 3 or 6 months. Program failure was defined as the detection of HCC exceeding the Milan criteria. Variables recorded at entry into the program, during follow-up and at HCC diagnosis, were analyzed.
RESULTS: At diagnosis, 50 (26.6%) HCC tumors were beyond the Milan criteria. In univariate analysis, Child-Pugh B at entry (P = 0.03), development of complications of portal hypertension before tumor diagnosis (P = 0.03), and failure to complete the prior screening round (P = 0.02), Child-Pugh B/C (P = 0.001) and AFP ≥ 100 ng/mL (P = 0.03) at diagnosis, were associated with failure. In multivariate analysis, only Child-Pugh B/C (hazard ratio, 3.18; 95% confidence interval, 1.66-6.10, P < 0.001) and AFP ≥ 100 ng/mL, both at diagnosis (hazard ratio, 2.80; 95% confidence interval, 1.37-5.71, P = 0.005), were independently associated with failure. Survival was higher among patients with tumors within the Milan criteria than those with program failure (33.9 vs 7.6 months, P < 0.001).
CONCLUSIONS: Approximately 25% of HCC cases diagnosed among patients included in a surveillance program were beyond the Milan criteria. Child-Pugh B/C and AFP ≥ 100 ng/mL at diagnosis were associated with program failure. However, Child-Pugh B at entry and development of liver-related complications during follow-up can be early predictors of failure.
© 2018 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  clinical; epidemiology; hepatocellular carcinoma; portal hypertension; treatment

Mesh:

Year:  2018        PMID: 29384236     DOI: 10.1111/jgh.14108

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  8 in total

Review 1.  Recent Advances in Molecular Mechanisms of the NKG2D Pathway in Hepatocellular Carcinoma.

Authors:  Jian Wang; Cun-Di Li; Lin Sun
Journal:  Biomolecules       Date:  2020-02-14

2.  A Comparison of Biannual Two-Phase Low-Dose Liver CT and US for HCC Surveillance in a Group at High Risk of HCC Development.

Authors:  Jeong Hee Yoon; Jeong Min Lee; Dong Ho Lee; Ijin Joo; Ju Hyun Jeon; Su Joa Ahn; Seung-Taek Kim; Eun Ju Cho; Jeong-Hoon Lee; Su Jong Yu; Yoon Jun Kim; Jung-Hwan Yoon
Journal:  Liver Cancer       Date:  2020-08-06       Impact factor: 11.740

3.  Serum microRNA let-7a-1/let-7d/let-7f and miRNA 143/145 Gene Expression Profiles as Potential Biomarkers in HCV Induced Hepatocellular Carcinoma.

Authors:  Doaa Mamdouh Aly; Nadida Abdul-Hameed Gohar; Afaf Ahmed Abd El-Hady; Marwa Khairy; Mona Mohsen Abdullatif
Journal:  Asian Pac J Cancer Prev       Date:  2020-02-01

4.  Failure of hepatocellular carcinoma surveillance: inadequate echogenic window and macronodular parenchyma as potential culprits.

Authors:  Yeun-Yoon Kim; Chansik An; Do Young Kim; Khalid Suliman Aljoqiman; Jin-Young Choi; Myeong-Jin Kim
Journal:  Ultrasonography       Date:  2019-01-17

5.  Impact of ultrasonographic blind spots for early-stage hepatocellular carcinoma during surveillance.

Authors:  Junghwan Lee; Su Bee Park; Soyoung Byun; Ha Il Kim
Journal:  PLoS One       Date:  2022-09-16       Impact factor: 3.752

Review 6.  Nicotinamide N-Methyltransferase as Promising Tool for Management of Gastrointestinal Neoplasms.

Authors:  Valentina Pozzi; Roberto Campagna; Davide Sartini; Monica Emanuelli
Journal:  Biomolecules       Date:  2022-08-24

7.  MiR-494-3p promotes PI3K/AKT pathway hyperactivation and human hepatocellular carcinoma progression by targeting PTEN.

Authors:  Hui Lin; Zhi-Ping Huang; Jiao Liu; Yun Qiu; Yuan-Ping Tao; Meng-Chao Wang; Hui Yao; Ke-Zhu Hou; Fang-Ming Gu; Xuan-Fu Xu
Journal:  Sci Rep       Date:  2018-07-11       Impact factor: 4.379

8.  HDNA methylation data-based molecular subtype classification related to the prognosis of patients with hepatocellular carcinoma.

Authors:  Hui He; Di Chen; Shimeng Cui; Gang Wu; Hailong Piao; Xun Wang; Peng Ye; Shi Jin
Journal:  BMC Med Genomics       Date:  2020-08-24       Impact factor: 3.063

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.